Comparison of [68Ga]Ga-PSMA-HBED-CC PET versus Whole-Body Bone Scintigraphy for the Detection of Bone Metastases in Patients with Prostate Cancer

Abstract: Introduction: The prostate-specific membrane antigen (PSMA) is a transmembrane protein, that is highly expressed on the surface of prostate cancer cells. In the last few years, several PSMA-specific ligands have been developed, that can be successfully used to detect primary prostate cancer, tumor recurrences and metastases as well. Aim: The goal of our work was to examine the clinical application of a 99mtechnetium-labeled PSMA-radiopharmaceutical as part of the routine diagnostics of prostate cancer. Method: We examined 15 male patients with verified prostate adenocarcinoma with suspicion of progression or recurrence of the disease. We performed whole-body PSMA-SPECT/CTs and multiparametric MRIs of the prostate and the pelvic regions within a week. We used 99mTc-mas3-y-nal-k(Sub-KuE) for the PSMA-SPECT scans. The images were visually evaluated by independent observers. The results were compared with the follow-up bone scintigraphies as well. Results: Twenty-two PSMA-positive lesions were found. Nine of them were localized outside, 13 were within the MRI’s field of view. From these 13 lesions, 7 matched with the SPECT/CT results and in 5 cases the MRI images showed no abnormalities. In one case, bone metastasis was suspected on the MRI scan but there was no corresponding pathological tracer uptake on the SPECT images. In two patients, none of the examinations showed signs of prostate malignancy. Four patients had PSMA-positive bone metastases. One of them had a matching PSMA/SPECT and bone scintigraphy result and in one case the PSMA examination showed metastasis in contrast to the negative bone scintigraphy. Conclusion: PSMA-SPECT/CT with 99mTc-mas3-y-nal-k(Sub-KuE) is a promising diagnostic tool. This technique is capable of visualizing bone metastases and it can detect local recurrences and visceral metastases as well. Orv Hetil. 2018; 159(35): 1433–1440.

Download Full-text

Does whole-body bone SPECT/CT provide additional diagnostic information over [18F]-FCH PET/CT for the detection of bone metastases in the setting of prostate cancer biochemical recurrence?

Cancer Imaging ◽

10.1186/s40644-020-00333-y ◽

2020 ◽

Vol 20 (1) ◽

Cited By ~ 1

Author(s):

Nicolas de Leiris ◽

Julien Leenhardt ◽

Bastien Boussat ◽

Christopher Montemagno ◽

Alexandre Seiller ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Biochemical Recurrence ◽

Diagnostic Information ◽

Whole Body ◽

Additional Diagnostic Information ◽

Pet Ct ◽

Bone Spect ◽

Body Bone

Download Full-text

Bone Metabolism of the Patient with a Malignant Melanoma during the Entry Examination and the Check-up of Whole-body Bone Scintigraphy

Prague Medical Report ◽

10.14712/23362936.2016.14 ◽

2016 ◽

Vol 117 (2-3) ◽

pp. 129-134

Author(s):

Jaroslav Weissensteiner ◽

Eva Babušíková

Keyword(s):

Malignant Melanoma ◽

Bone Metastases ◽

Bone Metabolism ◽

Bone Scintigraphy ◽

Type I Collagen ◽

Tumour Marker ◽

Whole Body ◽

Type I ◽

Negative Finding ◽

Body Bone

Malignant melanoma is a malignancy located predominantly in the skin and the incidence of melanoma increases. We compared the markers of bone metabolism – osteocalcin (OC), beta-carboxyterminal cross-linked telopeptide of type I collagen (β-CrossLaps, β-CTx) and tumour marker – human epididymis protein 4 (HE4) in the serum with finding during the entry examination and the check-up of whole-body bone scintigraphy of the patient with a malignant melanoma. Serum concentrations of OC, β-CTx, HE4 were determined in 1 patient (female, age 64 years) with malignant melanoma and correlated with the presence of equivocal bone metastases detected by whole-body bone scintigraphy (the entry examination and check-up after 6 months). Concentrations of bone metabolism markers decreased during six months and we observed progress in bone metastases. The change of the markers levels during the entry examination and the check-up of the whole-body bone scintigraphy with equivocal finding of bone metastases could be a sign of a possible initiating progression of malignant melanoma despite a clinically negative finding that does not prove the progression of the disease.

Download Full-text

Diagnostic performance of whole-body bone scintigraphy in combination with SPECT/CT for detection of bone metastases

Annals of Nuclear Medicine ◽

10.1007/s12149-020-01488-1 ◽

2020 ◽

Author(s):

Yiqiu Zhang ◽

Beilei Li ◽

Bing Wu ◽

Haojun Yu ◽

Junyi Song ◽

...

Keyword(s):

Bone Metastases ◽

Bone Scintigraphy ◽

Diagnostic Performance ◽

Whole Body ◽

Body Bone

Download Full-text

Comparison of the Whole-Body Bone Scintigraphy with Levels of the Markers of Bone Metabolism in Serum of Patients with Malignant Melanoma

Acta Medica Martiniana ◽

10.1515/acm-2015-0001 ◽

2015 ◽

Vol 5 (1) ◽

pp. 5-11 ◽

Cited By ~ 1

Author(s):

J. Weissensteiner ◽

E. Babusikova

Keyword(s):

Malignant Melanoma ◽

Bone Metastases ◽

Bone Metabolism ◽

Bone Scintigraphy ◽

Type I Collagen ◽

Whole Body ◽

Type I ◽

Control Subjects ◽

Body Bone ◽

Physiological Value

Abstract Objective. The aim of this study was to evaluate serum levels of the biochemical markers of bone metabolism: osteocalcin (OC), beta-carboxyterminal cross-linked telopeptide of type I collagen (β-CTx) with the presence of bone metastases detected by whole-body bone scintigraphy in patients with malignant melanoma. Methods. We determined the markers of bone metabolism in the serum by electrochemiluminescent immunoanalysis in 14 patients with melanoma and in 10 persons without malignant disease (control subjects). All participants were examined by whole-body bone scintigraphy using hybrid scanner of type BrightView XCT. Results. The bone metastases by whole-body bone scintigraphy were in 5 cases, probably in 3 cases and 6 patients were without bone metastases from 14 patients (4 men, 10 women). The concentration of OC in patients was lower about 25.4% in comparison with control subjects. The concentration of OC in the serum was below physiological value in 6 patients and in 4 cases with bone metastases. The concentration of β-CTx was below physiological value in 3 patients and in 2 cases with bone metastases. Conclusion. We observed lower concentration of osteocalcin in patients with malignant melanoma compared to control subjects and the lowest ostecalcin concentration was observed in patients with bone metastases. We did not observe changes in the concentration of beta-carboxyterminal cross-linked telopeptide of type I collagen compared neither to control subjects nor between patients with or without bone metastases.

Download Full-text